Payer access

As the number of rare disease drugs on the market exponentially increases, marketers will have to ramp up efforts to persuade payers of the value of these often costly treatments.

Maria Fontanazza

Most of us engage with social media at least once day. I am being pretty conservative as I write that statement. On a global scale, a person spends an average of 2.25 hours a day on social media. And for those of us who work in media or healthcare communications, we are on and off social media all day, pretty much every day. On this professional scale, we use social media to educate and engage with our audience. 

laptop, report

Blockbuster deals are on the rise as drug manufacturers navigate through patent cliffs, pricing pressures, and evolving regulations while M&A activity remains an integral part of the strategic landscape.

Dan Renick, Petauri Health

Although prescription drug pricing tends to dominate national media coverage – with a frequent focus on cost as a barrier to patient access – that is only one aspect of a complex and often convoluted experience for patients, especially when highly specialized treatments are needed.

Carl Foster, Standigm

Can recent breakthroughs in artificial intelligence (AI) accelerate the development of personalized medicine?

Safety, regulatory, quality and medical information executives at IQVIA discuss key industry trends and challenges for lifescience companies.

Melissa Mooney, IQVIA

In a wave of advanced technology and decentralized clinical trials, sponsors have turned to electronic tools such as electronic clinical outcome assessments (eCOAs) to capture patient reported outcomes data.

hub program, patients first

Every patient services program, or hub program, claims to keep the patient journey in mind. But how many hub services providers actually put in the rigor required to create a journey that addresses the breadth of patient needs – much less how those needs change from therapy to therapy?

Doctor, cell phone

The customer experience provided to HCPs in the United States is approaching an inflection point, as unsustainable marketing investment choices face a looming reckoning.


Although the bulk of gene therapy research is still focused on rare disease, recent launches show that certain chronic conditions could be successfully treated with this technology.